Word

AVAXZIPEN

Status

Pending

Status Code

661

Status Date

Wednesday, September 25, 2024

Serial Number

79388905

Mark Type

4

Filing Date

Friday, March 31, 2023

Trademark Owner History

AVAXZIPEN LIMITED

Classifications

5 Pharmaceutical, biopharmaceutical and veterinary preparations and substances for the treatment of and protection against disease; pharmaceutical, biopharmaceutical and veterinary preparations and substances for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders; prophylactic pharmaceutical and veterinary preparations and substances, namely for the treatment of infectious and autoimmune diseases; vaccines; prophylactic vaccines; therapeutic vaccines; vaccine preparations; biological preparations for medical use, namely, mixed biological preparations for the prevention and treatment of infectious and autoimmune diseases; biological, chemical and biochemical reagents for medical use; contraceptive preparations and substances, namely, oral, chemical and parenteral based contraceptives

10 Surgical apparatus and instruments; medical, dental and veterinary apparatus and instruments, namely, injection and infusion devices for administering pharmaceutical, biopharmaceutical and veterinary preparations; drug delivery devices sold empty, namely, injection devices; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations parenterally; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into subcutaneous tissue; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intradermal tissue; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intramuscular tissue; drug delivery devices, namely, drug cassettes sold empty; drug delivery devices, namely medical injectors, needle-free injectors, injectors with needles, all sold empty; drug delivery devices, sold empty, namely, medical injectors, needle-free injectors and parts and fittings therefore; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices for injecting pharmaceutical, biopharmaceutical and veterinary preparations parenterally; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into subcutaneous tissue; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intradermal tissue; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intramuscular tissue; pre-loaded drug cassettes for use in drug delivery devices to contain pharmaceutical and biopharmaceutical preparations and substances for therapeutic, prophylactic and diagnostic use; Structural parts and fittings for all the aforesaid goods

42 Medical and veterinary research and product development services; medical and veterinary device development services; pharmaceutical and biopharmaceutical development services; Product development of pharmaceutical and biopharmaceutical delivery systems; Pharmaceutical and biopharmaceutical product development, namely research and formulation of pharmaceuticals and biopharmaceuticals; research into vaccines; Product testing services for medical and veterinary devices and products; provision of information relating to product development and testing; Consulting services in the field of product development and testing

Trademark Events

Feb 9, 2024

Sn Assigned For Sect 66a Appl From Ib

Feb 12, 2024

New Application Office Supplied Data Entered

Feb 16, 2024

Application Filing Receipt Mailed

Feb 12, 2024

Assigned To Examiner

Mar 25, 2024

Refusal Processed By Mpu

Sep 24, 2024

Correspondence Received In Law Office

Sep 24, 2024

Teas Response To Office Action Received

Sep 25, 2024

Teas/Email Correspondence Entered

Apr 16, 2024

Refusal Processed By Ib

Mar 1, 2024

Non-Final Action Written

Mar 2, 2024

Non-Final Action (Ib Refusal) Prepared For Review

Mar 25, 2024

Non-Final Action Mailed - Refusal Sent To Ib